AJP - Heart AJP: Gastrointestinal and Liver Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 280: H2823-H2832, 2001;
0363-6135/01 $5.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rastaldo, R.
Right arrow Articles by Pagliaro, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rastaldo, R.
Right arrow Articles by Pagliaro, P.
Vol. 280, Issue 6, H2823-H2832, June 2001

Cytochrome P-450 metabolite of arachidonic acid mediates bradykinin-induced negative inotropic effect

R. Rastaldo2, N. Paolocci3, A. Chiribiri1, C. Penna1, D. Gattullo1, and P. Pagliaro1

1 Dipartimento di Scienze Cliniche e Biologiche and 2 Dipartimento di Neuroscienze, Sezione di Fisiologia, dell'Università di Torino, 10043 Orbassano (TO), Italy; and 3 Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-6568


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

This study focused on the mechanisms of the negative inotropic response to bradykinin (BK) in isolated rat hearts perfused at constant flow. BK (100 nM) significantly reduced developed left ventricular pressure (LVP) and the maximal derivative of systolic LVP by 20-22%. The cytochrome P-450 (CYP) inhibitors 1-aminobenzotriazole (1 mM and 100 µM) or proadifen (5 µM) abolished the cardiodepression by BK, which was not affected by nitric oxide and cyclooxygenase inhibitors (35 µM NG-nitro-L-arginine methyl ester and 10 µM indomethacin, respectively). The CYP metabolite 14,15-epoxyeicosatrienoic acid (14,15-EET; 50 ng/ml) produced effects similar to those of BK in terms of the reduction in contractility. After the coronary endothelium was made dysfunctional by Triton X-100 (0.5 µl), the BK-induced negative inotropic effect was completely abolished, whereas the 14,15-EET-induced cardiodepression was not affected. In hearts with normal endothelium, after recovery from 14,15-EET effects, BK reduced developed LVP to a 35% greater extent than BK in the control. In conclusion, CYP inhibition or endothelial dysfunction prevents BK from causing cardiodepression, suggesting that, in the rat heart, endothelial CYP products mediate the negative inotropic effect of BK. One of these mediators appears to be 14,15-EET.

endothelium; epoxyeicosatrienoic acids; myocardial contractility; left ventricular pressure; coronary perfusion pressure


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

BRADYKININ (BK) is a well-known endothelium-dependent vasodilator that affects coronary resistance and myocardial contractility (3, 12, 17, 33, 34, 38, 39, 47). Its production can increase during myocardial ischemia (39) and angiotensin-converting enzyme inhibition, which protects BK from inactivation (38). While vasodilatation depends on the release of endothelial factors such as nitric oxide (NO), prostacyclin, and endothelium-derived hyperpolarizing factor (EDHF) (5, 6, 8, 13-18, 20-22, 35, 36, 38, 49, 50, 54-57), the mechanisms leading to changes in myocardial contractility have not yet been fully investigated.

BK may have a positive inotropic effect, which is attributed to an increase in sympathetic discharge (33, 34) or to Gregg's phenomenon (34, 39). However, in many preparations in which these two mechanisms are limited, BK has a negative inotropic effect that seems mediated by endothelial factor(s) (3, 12, 17, 44). For example, Ou et al. (44) reported that endothelial factor(s) can induce a reduction in the calcium transient of electrically stimulated cardiomyocytes and that BK further reduces the amplitude of this transient by acting on the endothelium. However, the nature of this cardiodepressive factor is still unknown. It is possible that one of the endothelial vasodilator pathways activated by BK is also responsible for the endothelium-mediated negative inotropic effect.

One of the endothelial factors involved in the cardiodepression could be NO. However, NO has a bimodal action on contractility that depends on its concentration and the experimental model (3, 4, 17, 27, 28). For example, NO inhibition completely abolishes BK-induced contractile depression in isolated guinea pig cardiomyocytes (3) but not in the ferret heart (17). Moreover, in many species (including humans), the vasodilatation caused by BK is largely dependent on EDHF rather than NO (35, 36, 45); in particular, in the rat heart, NO and prostaglandins have been seen to play a trivial, if any, role in vasodilator responses to BK (20, 21). These findings suggest that the isolated rat heart can be an adequate model to study whether compounds different from NO are involved in the endothelium-mediated cardiodepression induced by BK.

A cytochrome P-450 (CYP) monoxygenase metabolite of arachidonic acid, namely, one of the epoxyeicosatrienoic acids (EETs), has been reported to be responsible for BK-induced vasodilatation in the rat coronary circulation (20, 21) and has been proposed as the most likely candidate for the role of EDHF in the coronary bed of many species (1, 5, 6, 8, 15, 16, 20, 21, 35, 49, 50, 55, 57). In porcine coronary arteries, CYP 2C fulfils the property of EDHF synthase (16). Indeed, BK can activate both CYP and a membrane phospholipase, which causes the release of arachidonic acid from phospholipids, thus providing the substrate to CYP for the formation of various EETs (5, 6, 14, 30, 55, 57). These are incorporated into the membrane phospholipids of endothelial and smooth muscle cells, from which they are released by the hydrolizing activity of BK (14, 30, 55, 57). Thus BK could be responsible for both the production and release of various CYP products from the endothelium. Yet while only one EET is likely to be EDHF (5, 6, 15, 16, 21, 49, 50), data on the role of the other CYP products remain scant, many of them concerning solely the vasomotor effects.

Because the relative contribution of EDHF/EET to vasodilatation is greater in microvessels, which lie in juxtaposition to cardiomyocytes (3), than in conduit arteries (8, 35, 36, 49, 50) and because EETs are diffusible compounds that act on a number of membrane channels [sodium (30), Ca2+-dependent potassium (5, 6, 15, 35, 36), and L-type calcium channels (7)], we hypothesized that one or more EET, released by the endothelium, can influence heart contractility.

Therefore, our study investigated whether the CYP pathway is involved in the negative inotropic response induced by BK and whether EETs mediate this response. In isolated rat hearts perfused at constant flow, we assessed the effects of BK infusion on left ventricular pressure (LVP) and coronary perfusion pressure (CPP) before and after the administration of 1-aminobenzotriazole (ABT) or proadifen, two structurally different inhibitors of CYP activity, with and without inhibition of NO synthase (NOS) and cyclooxygenase (COX). We also investigated whether perfusion with solutions containing EETs induces cardiodepression and/or vasodilatation. Finally, we examined whether the responses of the myocardium and vasculature to BK were affected by the preliminary administration of EETs.


    METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

Isolated hearts of male Wistar rats (n = 77, 450-550 g body wt) were retrogradely perfused with oxygenated buffer solution at 37°C. Flow was kept constant using a pump titrated to a CPP of 85-90 mmHg. Constant flow was used to limit confounding alterations in contractility due to Gregg's phenomenon (11, 12). A little hole in the left ventricular wall allowed the drainage of the thebesian flow. A polyvinyl chloride balloon was placed in the left ventricle and connected to an electromanometer to record LVP. The balloon was filled with saline at an end-diastolic LVP of 5-15 mmHg to achieve a maximum isovolumic developed LVP. The hearts were paced at 280-300 beats/min. CPP and coronary flow (CF) were monitored with another electromanometer and an electromagnetic flow probe, respectively, both placed along the perfusion line. Tyrode solution perfusate was oxygenated with 100% O2 and contained (in mmol/l) 154 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 5.5 D-glucose, and 5 HEPES; pH was adjusted to 7.35 with NaOH. Because controversy exists (1, 2, 25, 32, 48-51) as to whether HEPES-buffered solutions (i.e., without CO2/HCO<UP><SUB>3</SUB><SUP>−</SUP></UP>) can alter endothelial function through the induction of intracellular acidosis, to ascertain a possible role of the buffer on BK effects, in a separate group of hearts (see Experimental Protocols) the Krebs-Henseleit solution (gassed with 95% O2-5% CO2) was used. The composition of the solution was as follows (in mmol/l): 144 sodium, 5 potassium, 1.5 calcium, 17.5 bicarbonate, 1.2 magnesium, 11 D-glucose, and 134 chloride, along with 5 µg/ml lidocaine. The results of this group were compared with those obtained with HEPES-buffered solution.

LVP, CF, and mean CPP were recorded using a TEAC R-71 recorder, digitized at 600 Hz, and analyzed offline with DataQ Instruments/CODAS software, which allowed us to determine the maximum rate of increase of LVP in systole (dP/dtmax). Because CF was kept constant, variations of CPP revealed changes in coronary resistance (CPP/CF). Experimental animals were used in accordance with Italian law (DL-116, January 27, 1992) and conformed to the "Guiding Principles for Research Involving Animals and Human Beings" approved by the Council of the American Physiological Society.

Experimental Protocols

The hearts were allowed to stabilize for 20-30 min before baseline values were recorded. The following six groups were used:

Group 1: BK before and during ABT. In six hearts, a 3-min BK infusion (100 nM) was performed, and a washout period of 20-30 min was monitored. To block CYP activity, ABT, which is reported to be a long-lasting inhibitor of CYP (5, 31, 43), was then infused at the concentration of 1 mM for 10 min and then at the concentration of 100 µM for 5 min. After these 5 min had elapsed, BK (100 nM) was coinfused for 3 min with ABT (100 µM). The infusion of ABT (100 µM) alone was then continued for 20-30 min to verify the persistence of steady-state conditions. The concentration of ABT was reduced from 1 to 100 µM to limit possible disturbing side effects unrelated with CYP inhibition. Moreover, to determine whether CYP was still blocked after ABT was washed out, we performed six additional experiments in which BK was infused starting after a washout period of 10 min from the end of the administration of ABT. To give these hearts the same amount of ABT received by the other ABT-treated hearts, the substance was infused at a concentration of 1.05 mM for 10 min.

Group 2: BK before and during proadifen. To further support the hypothesis that the inhibition of BK effect by ABT was not due to a nonspecific effect of the drug, proadifen, a structurally different inhibitor of CYP (6), was used. In five hearts, a 3-min BK infusion (100 nM) was performed, and a washout period of 20-30 min was monitored. Proadifen (5 µM) was then infused for 10 min. After this period, BK (100 nM) was coinfused with proadifen for 3 min. The infusion of proadifen (5 µM) alone was then continued for 20-30 min to verify the persistence of steady-state conditions.

Group 3: BK before and after NG-nitro-L-arginine methyl ester + indomethacin and after ABT. In seven hearts, BK infusion (100 nM) was performed before and after 10 min of coinfusion of NG-nitro-L-arginine methyl ester (L-NAME; 35 µM) (29), a NOS inhibitor, plus indomethacin (Indo; 10 µM) (3, 17, 36), a COX inhibitor. When the effects of the second BK infusion were over, ABT was added at the same dose as in group 1, and BK was infused again. In four additional hearts, the same protocol was followed except that Tyrode solution was replaced with Krebs-Henseleit solution.

Group 4: BK before and after Triton X-100. In eight hearts, BK infusion (100 nM) was performed before and after the endothelium was made dysfunctional by a 0.1-ml injection of Triton X-100 (5 µl/ml) (12, 17). In four of these hearts, the specificity of the endothelial dysfunction was checked by the infusion of sodium nitroprusside (SNP; 100 µM) before and after Triton X-100. Finally, in two of these hearts, at the end of the experiment the cardiodepressive capability of verapamil (2.5 µM) was tested.

Group 5: BK before and after EETs. BK (100 nM) infusion was performed before and after various EETs [8,9-EET (n = 9), 11,12-EET (n = 6), or 14,15-EET (n = 9)] were infused separately at a concentration ranging from 10 to 50 ng/ml (corresponding to 0.03-0.16 µM) for 20 min. To verify whether the effects of EETs were endothelium dependent, in seven additional hearts, 11,12-EET (50 ng/ml, n = 3) and 14,15-EET (50 ng/ml, n = 4) infusions were performed before and after the endothelium was made dysfunctional, as in the hearts of group 4.

Group 6: role of BK tachyphylaxis. To exclude a role of tachyphylaxis, in five hearts, three sequential 3-min BK (100 nM) infusions were performed, separated from each other by 30 min of washout. In five additional hearts, the 3-min BK (100 nM) infusion was performed only after proadifen (5 µM) had been infused for 20 min.

Materials

The drugs used in these experiments were made to required concentration in the buffer solutions. The compounds were obtained from Sigma (St. Louis, MO), ICN (EETs; Costa Mesa, CA), Chiesi (Indo; Parma, Italy), and Roche (heparin; Milano, Italy).

Data analysis

Data are presented as means ± SD. For comparison of paired samples in each group, Student's t-test for paired data was used. Between intervention effects were first tested by ANOVA, and individual comparisons were then made with Student's nonpaired t-test, using a Bonferroni correction for multiple comparisons.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

After stabilization, in the 73 hearts perfused with Tyrode solution, developed LVP was 71 ± 8 mmHg, dP/dtmax was 1,075 ± 167 mmHg/s, and CPP was 87 ± 9 mmHg. These values were not statistically different from those of the control conditions of each group. In 61 hearts in which the 3-min BK infusion was performed in control conditions, a significant (P < 0.001) reduction in developed LVP (-21 ± 7%), dP/dtmax (-22 ± 10%), and CPP (-23 ± 11%) occurred, which recovered within 20-30 min. The BK effects in control conditions and after the administration of the various agents are reported in Table 1.

                              
View this table:
[in this window]
[in a new window]
  		Table 1.   BK effects in the presence of different conditions

Group 1: BK Before and During ABT

Figure 1A displays an example of developed LVP and CPP responses to BK before and during ABT. The results obtained in these hearts are summarized in Table 1 and Fig. 1B.


View larger version (39K):
[in this window]
[in a new window]
  		Fig. 1.   Effects of bradykinin (BK) infusion in baseline conditions and during cytochrome P-450 inhibition by 1-aminobenzotriazole (ABT). A: example showing the traces of coronary perfusion pressure (CPP) and left ventricular pressure (LVP). B: mean values showing the percent variation of each parameter relative to just before drug infusion. dP/dtmax, maximum rate of increase of LVP in systole; CR, coronary resistance. *P < 0.05 vs. pre-BK.

In these hearts, BK infusion caused a significant reduction of developed LVP (from 72 ± 13 to 55 ± 20 mmHg, P < 0.01), dP/dtmax (from 998 ± 174 to 769 ± 282 mmHg/s, P < 0.05), and CPP (from 89 ± 7 to 75 ± 9 mmHg, P < 0.05). During ABT infusion and before the second BK infusion, ventricular and perfusion pressure values, after an initial transient (2-4 min) increase, were not significantly different from the control. The second infusion of BK, given in coinfusion with ABT, did not affect developed LVP, dP/dtmax, and CPP (Table 1). In six additional hearts in which the administration of ABT was followed by the washout period, the first BK infusion reduced developed LVP, dP/dtmax, and CPP by ~20-25%. Ten minutes after the end of ABT infusion, the second administration of BK did not alter developed LVP, dP/dtmax, and CPP (Fig. 2).


View larger version (32K):
[in this window]
[in a new window]
  		Fig. 2.   Effects of BK infusion on developed LVP (DLVP), dP/dtmax, and CPP in baseline conditions and 10 min after the infusion of ABT was stopped (n = 6). *P < 0.05 vs. pre-BK.

Group 2: BK Before and During Proadifen

Figure 3A displays an example of developed LVP and CPP responses to BK during proadifen infusion. The results of this group are summarized in Table 1 and Fig. 3B.


View larger version (37K):
[in this window]
[in a new window]
  		Fig. 3.   Effects of BK infusion during cytochrome P-450 inhibition by proadifen (PRF). A: example showing traces of CPP and LVP. B: mean values showing the percent variation of each parameter relative to just before drug infusion.

In this group, BK infusion caused a significant reduction of developed LVP (from 70 ± 11 to 55 ± 15 mmHg, P < 0.01), dP/dtmax (from 988 ± 154 to 759 ± 272 mmHg/s, P < 0.05), and CPP (from 90 ± 7 to 75 ± 10 mmHg, P < 0.05). During proadifen and before the second BK infusion, developed LVP and dP/dtmax were not significantly different from the control. Also in this group, the second infusion of BK, given in coinfusion with proadifen, did not affect developed LVP, dP/dtmax, and CPP (Table 1).

Group 3: BK Before and After L-NAME + Indo and After ABT

Figure 4A displays an example of developed LVP and CPP responses to BK in this group. The results are summarized in Table 1 and Fig. 4B.


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 4.   Effects of BK infusion in baseline conditions, during nitric oxide (NO) + cyclooxygenase (COX) inhibition [by NG-nitro-L-arginine methyl ester (L-NAME) and indomethacin (Indo), respectively] and during NO + COX + cytochrome P-450 inhibition (by addition of ABT) in the heart perfused with Tyrode solution. A: example showing traces of CPP and LVP. B: mean data showing the percent variation of each parameter considered relative to just before drug infusion. *P < 0.05 vs. pre-BK; dagger P < 0.05 vs. "baseline BK effects."

In the seven hearts in which the Tyrode solution perfusate was used, the first BK infusion caused the usual significant reduction of developed LVP (from 69 ± 6 to 56 ± 8 mmHg, P < 0.01) and dP/dtmax (from 1,249 ± 197 to 1,032 ± 209 mmHg/s, P < 0.01). After NOS + COX inhibition, the second BK infusion also significantly reduced developed LVP and dP/dtmax (Table 1). It is noteworthy that NOS + COX inhibition "per se" did not alter basal contractility (dP/dtmax 1,249 ± 197 vs. 1,276 ± 198 mmHg/s).

CPP, which was significantly (P < 0.005) reduced (from 97 ± 7 to 77 ± 4 mmHg) by the first BK infusion, was significantly increased (+39%, P < 0.02) by NOS + COX inhibition and was not affected by the second BK infusion (Table 1).

After the effects of the second BK infusion were over, ABT did not significantly affect developed LVP, dP/dtmax, and CPP. In the presence of ABT, the third BK infusion was ineffective on both contractility and CPP (Table 1).

The failure of BK to induce evident vasodilatation suggested a possible alteration of the endothelial function by interaction of NOS + COX inhibition with HEPES (25). To test this hypothesis, experiments were performed using the Krebs-Henseleit solution. In the four Krebs-Henseleit solution-perfused hearts, after stabilization, developed LVP was 67 ± 2 mmHg, dP/dtmax was 1,058 ± 209 mmHg/s, and CPP was 94 ± 6 mmHg. The 3-min BK infusion, performed in control conditions, induced the usual significant (P < 0.05) reduction in developed LVP (-22 ± 5%), dP/dtmax (-20 ± 10%), and CPP (-17 ± 2%). After NOS + COX inhibition, in these hearts, BK also reduced the contractility (developed LVP from 65 ± 6 to 54 ± 4 mmHg, P < 0.05, and dP/dtmax from 950 ± 99 to 792 ± 86 mmHg/s, P < 0.05) but did not alter CPP significantly (from 156 ± 28 to 151 ± 24 mmHg, P = 0.15). Thus these results supported the idea that the absence of vasodilator response could not be ascribed to altered endothelial function by HEPES.

Group 4: BK Before and After Endothelium Was Made Dysfunctional by Triton X-100

Whereas in baseline conditions BK infusion had the usual reducing effect on developed LVP, dP/dtmax, and CPP (e.g., developed LVP decreased from 69 ± 7 to 56 ± 9 mmHg, -17%, P < 0.005), it did not produce any effect on myocardial contractility and CPP after the endothelium was made dysfunctional by Triton X-100 (Table 1). The results of this group are similar to those reported by other authors (12, 17). It is noteworthy that Triton X-100 did not affect basal contractility, whereas it increased CPP similar to L-NAME + Indo. Despite the similarity of the effects induced by the two treatments, the subsequent infusion of BK was unable to reduce both contractility and coronary resistance only in the presence of endothelial dysfunction by Triton X-100.

In four of these hearts, the endothelium-independent vasodilator effect of SNP was not affected by Triton X-100 pretreatment. SNP reduced CPP by 25% but did not significantly affect heart contractility. Furthermore, at the end of the experiments, verapamil (an endothelium-independent cardiodepressor) reduced developed LVP by 40%, thus showing that Triton X-100 was effective in selectively disrupting the coronary vascular endothelium without affecting the myocardium.

Group 5: BK Before and After EETs

A 20-min infusion of 8,9-EET (n = 3), 11,12-EET (n = 3), or 14,15-EET (n = 3) (10-20 ng/ml, for all EETs) did not cause any change in CPP and LVP. The ineffectiveness of EET infusion is likely to depend on their incorporation in vascular membrane phospholipids (14, 30, 55, 57). It has been reported that stored EETs can be released after phospholipid hydrolysis induced by BK (14, 30, 55, 57). Therefore, to bypass vascular incorporation, higher doses of various EETs were used; 8,9-EET (n = 6), 11,12-EET (n = 3), and 14,15-EET (n = 6) were infused at the concentration of 50 ng/ml (corresponding to 0.16 µM) for 20 min, and the effects of BK infusion before and after various EETs were compared.

Of the various EET regioisomers tested, only 14,15-EET (50 ng/ml, n = 6) caused a reduction in contractility.

Figure 5A displays an example of developed LVP and CPP responses to BK in the hearts in which 14,15-EET was infused. The results are summarized in Table 1 and Fig. 5B.


View larger version (40K):
[in this window]
[in a new window]
  		Fig. 5.   Effects of BK infusion in baseline conditions and after 14,15-epoxyeicosatrienoic acid (EET) treatment. The effects of 14,15-EET itself are also shown. A: example showing traces of CPP and LVP. B: summary data showing percent variation of each parameters considered relative to just before drug infusion. *P < 0.05 vs. pre-BK; dagger P < 0.05 vs. baseline BK effects; Dagger P < 0.05 vs. "14,15-EET effects" and vs. baseline BK effects.

The first BK infusion reduced developed LVP (from 75 ± 14 to 59.5 ± 11 mmHg, P < 0.001) and dP/dtmax (from 1,026 ± 228 to 795 ± 223 mmHg/s, P < 0.001). After washout of BK effects, 14,15-EET infusion reduced developed LVP (from 74 ± 12 to 62 ± 12 mmHg, P < 0.005) and dP/dtmax (from 981 ± 208 to 818 ± 213, P < 0.005). These reductions were significantly lower (-21%, P = 0.033, and -26%, P = 0.036, respectively) than those obtained with BK infusion. After 5 min of washout to allow the recovery of contractile function, a second BK infusion showed potentiated effects in reducing myocardial contractility (Fig. 5B). In particular, the second BK infusion reduced developed LVP and dP/dtmax (Table 1) to a greater extent than the first one (+35%, P = 0.015, and +15%, P = 0.036, respectively).

The first BK infusion significantly reduced (P < 0.05) CPP. No effect on CPP was observed during 14,15-EET, whereas the second BK infusion again caused a significant (P < 0.05) reduction. No significant difference was seen between the effects of the two BK infusions on CPP.

In seven additional hearts, 11,12-EET (50 ng/ml, n = 3) and 14,15-EET (50 ng/ml, n = 4) were infused before and after the endothelium was made dysfunctional. It was observed that 11,12-EET was ineffective in altering heart contractility both before and after Triton X-100. On the contrary, the infusion of 14,15-EET induced a negative inotropic effect, which was similar before and after the endothelium was made dysfunctional. In particular, developed LVP and dP/dtmax were significantly reduced by 15% before and after Triton X-100.

Group 6: Role of BK Tachyphylaxis

BK induced a similar significant (P < 0.05) reduction by ~20% in developed LVP during each of the three sequential infusions. In the subset of hearts in which BK was infused only in the presence of proadifen, developed LVP was not affected, being 68 ± 2 mmHg before and 66 ± 3 mmHg during BK. From these results and those of group 5, in which the second dose of BK was more effective than the first one, any role of tachyphylaxis in the abrogation of BK-induced cardiodepression can be excluded.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

The major novel finding of this study is that the cardiodepressive effect caused by intracoronary administration of BK is the result of the endothelial release of CYP-dependent metabolites, one of which is likely to be 14,15-EET. The present results also indicate that the extent of BK-induced negative inotropic effect is enhanced by prior administration of 14,15-EET (Table 1 and Fig. 5). Because 14,15-EET did not induce evident vasodilatation, this particular EET is not likely to be the putative vasodilating EDHF. This last hypothesis is in agreement with many reports (e.g., Refs. 6, 15, 16, 20, and 21) that identified 5,6- or 11,12-EET as the most likely candidate for EDHF.

BK exerts an evident negative inotropic action only in isolated cardiomyocytes (44) or in hearts perfused at constant flow (3, 12, 17), i.e., when perfusion-dependent changes in contractility (Gregg's phenomenon) and sympathetic stimulation are limited. However, in isolated hearts, perfusion-induced changes in contractility do not seem completely prevented when a reduction in CPP occurs despite a constant flow (11). Because in our experiments both 14,15-EET alone and BK after NOS + COX inhibition induced a reduction in contractility despite unchanged CPP and flow, perfusion-related cardiodepression can be excluded as an effect of BK and/or 14,15-EET.

BK is unable to reduce contractility only after CYP inhibition or in the presence of endothelial dysfunction obtained with Triton X-100. These findings show for the first time that the endothelial CYP pathway is involved in BK-induced cardiodepression. Although CYP is an ubiquitous enzyme, EET involved in the BK-induced response must be of endothelial origin. This hypothesis is reinforced by the fact that the CYP enzyme system is more concentrated in vascular endothelial cells than in cardiomyocytes (47). Moreover, the endothelium of microvessels (<100 µm), which lies close to cardiomyocytes (3), releases more EETs than NO (8, 35, 36, 49, 50). Furthermore, in the presence of endothelial dysfunction, 14,15-EET still causes a reduction in contractility. This result reinforces the hypothesis that this particular EET is released by the endothelium in BK-induced cardiodepression. Finally, the observation that L-NAME + Indo did not prevent BK cardiodepression is also consistent with the study of Fort and Lewis (17), who reported that higher doses of BK (10-6 M) have an NO-independent cardiodepressive effect and excluded any role of endothelial autocoids different from CYP-dependent metabolites in the reduction of contractility by BK. This conclusion is based on the reported effectiveness of 35 µM L-NAME in inhibiting NOS and reducing CF in isolated rat hearts (29). Although higher doses may be required in some different preparations (9, 36), in our study, the fact that the addition of the CYP inhibitor ABT after NOS + COX inhibition abolished the cardiodepressive response to BK further supports the hypothesis that the response was not due to a residual NO release after L-NAME (9). Furthermore, it has been reported that the BK-induced cardiodepression is unaffected by COX inhibition with Indo (3, 17). However, the simultaneous inhibition of NOS and COX is required to ascertain the role of CYP products on the regulation of vasomotor tone (1, 5, 16, 38).

The endothelium-dependent coronary vasodilator effect of BK is reported to be largely dependent on EDHF rather than NO (20, 21, 35, 36, 45). In particular, in the rat heart, NO has been seen to play a trivial, if any, role in the vasodilatation by BK (20, 21). These observations are consistent with our finding that BK has no vasodilator effect after CYP inhibition. On the basis of these observations one might argue that, in the rat, CYP products (including EDHF) could be the sole endothelial factors involved in BK-mediated vasodilatation and cardiodepression. However, in apparent contrast to the above findings, vasodilatation by BK but not cardiodepression is also abolished by only NOS + COX inhibition regardless of the buffer used. A similar result has been obtained in a previous study (45) on anesthetized dogs to which low (intracoronary) doses of BK were given. This apparent discrepancy may reflect a dose- or a species-dependent effect. We can speculate that, depending on the experimental model, a concomitant release of NO, prostacyclin, and EET/EDHF may be required to induce an evident vasodilatation by BK. In fact, BK is responsible for the release of NO (3, 22) and of arachidonic acid from phospholipids, thus providing the substrate to activated CYP (5, 6, 21, 30, 47) for the formation of various EETs and to COX for the formation of prostacyclin (47). Inhibition of either or both pathways in the experimental conditions listed above fully prevents BK-induced vasodilatation. On the contrary, only the release of CYP products (including 14,15-EET) seems to be responsible for BK-induced cardiodepression in the rat. The CYP products, different from EDHF, can also counteract the potential positive inotropic effect of a low concentration of NO (28) without contributing to the vasodilatation.

Regarding the precise mechanisms by which BK/14,15-EET induces myocardial depression, several alternative hypothesis should be entertained. According to Chen et al. (7), a role for EETs could derive from their ability to reduce the open probability of myocardial L-type Ca2+ channels. It has also been reported that EDHF/EET acts on the smooth muscles by opening Ca2+-dependent potassium channels (5, 6, 15, 35, 36). By opening the myocardial Ca2+-dependent potassium channels (23), EETs could cause an early repolarization, with shortening of the plateau of the action potential and reduction of cellular calcium influx and concentration. This hypothesis is supported by recent data of Paolocci et al. (46), who have shown a role for Ca2+-dependent potassium channels in BK-induced cardiodepression. Although this may be true, the role of EETs on myocardial calcium influx is still controversial. In particular, 5,6- and 11,12-EET increase cell shortening and intracellular calcium concentrations, whereas low doses of 8,9- or 14,15-EET (1-16 ng/ml) are ineffective on these parameters (37). Recently, it has been demonstrated an effect of EETs, in particular 8,9-EET, reduces the open probability of sodium channels in isolated cardiomyocytes (30). All these findings (5-7, 15, 30, 35, 36, 47) suggest that EETs have ion channels as major targets and may be involved not only in the regulation of the contractile properties of myocardium but also in the stabilization of cardiac electrophysiology. However, the effects of the individual EETs on cardiac ion channels and functional consequences are not yet completely clear. Furthermore, the observation that CYP inhibition by imidazole antimycotics (59) suppresses L-type Ca2+ current in cardiomyocytes indicates that further studies are required to clarify which channels and mechanisms are involved in the cardiodepression by BK and 14,15-EET.

The inhibitors we used are not likely to affect myocardial L-type Ca2+ current; in fact, ABT and proadifen per se do not modify contractility. Unfortunately, the majority of CYP inhibitors have nonspecific inhibitory effects and do not solely block CYP activity but also inhibit ATP-sensitive potassium channels (5, 19, 54, 56). Hence, we used two structurally unrelated inhibitors, one of which (ABT) has a broad substrate specificity (43) and does not block potassium channels (5, 54, 56). Because only specific CYP inhibition should be long lasting, the efficacy of ABT even after a washout period of 10 min supports the hypothesis of an involvement of CYP products in BK-induced cardiodepression. Nevertheless, the fact that 14,15-EET reproduces and potentiates negative inotropic effects of BK further supports this hypothesis and limits the importance of possible side effects of the inhibitors.

The influence of the basal release of endothelial factors on contractility remains uncertain (for reviews, see Refs. 4, 27, and 28). Brutsaert et al. (4) reported that simultaneous inhibition of NO, PGI2, and endothelin-1 in isolated papillary muscle results in no change of baseline contractile performance. The present study also demonstrates that the basal release of CYP products does not affect baseline contractility because proadifen and ABT (alone or in association with L-NAME + Indo) do not significantly affect heart performance.

The potentation of BK-induced cardiodepression by 14,15-EET pretreatment seems to depend on the fact that part of the 14,15-EET infused is stored in the membrane phospholipids of vascular endothelial and smooth muscle cells and is then released when BK is given (14, 55, 57). Thus, when infused at low doses, EETs cannot reach the smooth muscle fibers and myocardium. Moffat et al. (37) reported that, in the guinea pig, low doses of EETs do not change cardiac function and coronary resistance, whereas after pretreatment with EETs, an exacerbation of the ischemia-reperfusion cardiodepression occurs. Because during ischemia-reperfusion BK can be released by the activity of a kininogenase on kininogen (30, 60), a BK-induced release of stored 14,55-EET can explain this exacerbation of cardiodepression. In addition, during ischemia, the cellular concentration of EETs and its release may be enhanced as a consequence of an increased release of arachidonic acid with subsequent CYP epoxygenation, activation of phospholipases, and oxidation-hydrolysis of membrane phospholipids (30, 41). Indeed, the amount of EETs released by the vascular wall is unknown, but in the human platelet it has been estimated to reach the micromolar range (61).

From our results, it seems that, at the dose used (nM range), EET isomers different from 14,15-EET are not involved in the negative inotropic effect of BK. The ineffectiveness of 8,9- and 11,12-EETs could derive from the fact that they are more avidly taken up by membrane phospholipids (15, 55, 57). Thus greater doses may be required to be effective or, alternatively, they are not involved in the cardiodepression induced by BK in the rat, as indicated by the fact that 20-30 nM of 11,12-EET induced an increase in L-type calcium current in isolated guinea pig (37) and rat (59) cardiomyocytes, whereas lower doses (2 nM) were ineffective (59).

Clinical Implications

CYP activity have been identified in hearts from several mammalian species, including rats and humans (24, 58), and may play an important role in the development of some diseases. In isolated guinea pig hearts, the exacerbation of the effects of ischemia-reperfusion by EETs supports this hypothesis (43). Furthermore, in many diseases (10, 18, 26, 53), a reduced NO-dependent vasodilatation has been described. Such a reduction is reported to lead to a disinhibition of CYP (1, 42), thus enhancing the release of CYP products. This mechanism can not only be responsible for the enhanced hyperpolarizing response, as seen in the hypercolesterolemic rabbit (40), but can also enhance the potential negative inotropic effect of the substances capable to activate CYP, as BK is.

In conclusion, this study provides a novel explanation for the negative inotropic effect of BK, which persists after NO inhibition, suggesting that, in the rat, the CYP pathway is the major physiological mechanism of BK-induced cardiodepressive response and that the relevant cytochrome is of vascular endothelial origin. The main product of CYP involved in the response may be 14,15-EET, which, on the other hand, is not likely to be responsible for vasodilatation. Finally, we cannot exclude that other CYP products, different from 14,15-EET, could be involved in the cardiodepressive response induced by BK.


    ACKNOWLEDGEMENTS

The authors express gratitude to Prof. David A. Kass and Prof. Gianni Losano for the critical reading of the manuscript.


    FOOTNOTES

This study was supported by "Compagnia di San Paolo" and the Italian Ministry of University and Scientific and Technological Research (ex40 and 60% grants to D. Gattullo and P. Pagliaro).

Address for reprint requests and other correspondence: P. Pagliaro, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Ospedale S. Luigi, Regione Gonzole 10, 10043 Orbassano (TO), Italy (E-mail: pasquale.pagliaro{at}unito.it).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4 August 2000; accepted in final form 16 February 2001.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Bauersachs, J, Popp R, Hecker M, Sauer E, Fleming I, and Busse R. Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94: 3341-3347, 1996[Abstract/Free Full Text].

2.   Behmanesh, S, and Kempski O. Mechanisms of endothelial cell swelling from lactacidosis studied in vitro. Am J Physiol Heart Circ Physiol 279: H1512-H1517, 2000[Abstract/Free Full Text].

3.   Brady, AJB, Warren JB, Poole-Wilson PA, Williams TJ, and Harding SE. Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol Heart Circ Physiol 265: H176-H182, 1993[Abstract/Free Full Text].

4.   Brutsaert, DL, Fransen P, Andries LJ, De Keulenaer GW, and Sys SU. Cardiac endothelium and myocardial function. Cardiovasc Res 38: 281-290, 1998[Abstract/Free Full Text].

5.   Campbell, WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78: 415-423, 1996[Abstract/Free Full Text].

6.   Campbell, WB, and Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 84: 484-488, 1999[Free Full Text].

7.   Chen, J, Capdevila JH, Zeldin DC, and Rosenberg RL. Inhibition of cardiac L-type calcium channels by epoxyeicosatrienoic acids. Mol Pharmacol 55: 288-295, 1999[Abstract/Free Full Text].

8.   Choen, RA, and Vanhoutte PM. Endothelium-dependent hyperpolarization: beyond nitric oxide and cyclic GMP. Circulation 92: 3337-3349, 1995[Free Full Text].

9.   Cohen, RA, Plane F, Najibi S, Huk I, Malinski T, and Garland CJ. Nitric oxide is the mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit carotid artery. Proc Natl Acad Sci USA 94: 4193-4198, 1997[Abstract/Free Full Text].

10.   Creager, MA, Cooke JP, Mendelsohn ME, Gallagher SJ, Coleman SM, Loscalzo J, and Dzau VJ. Impaired vasodilation of forearm resistance vessels in hypercholesterolemic humans. J Clin Invest 86: 228-234, 1990.

11.   Dijkman, MA, Heslinga JW, Sipkema P, and Westerhof N. Perfusion-induced changes in cardiac O2 consumption and contractility are based on different mechanisms. Am J Physiol Heart Circ Physiol 271: H984-H989, 1996[Abstract/Free Full Text].

12.   Dijkman, MA, Heslinga JW, Sipkema P, and Westerhof N. Perfusion-induced changes in cardiac contractility and oxygen consumption are not endothelium-dependent. Cardiovasc Res 33: 593-600, 1997[Abstract/Free Full Text].

13.   Eastman, CL, Harrison DG, Marcus ML, and Dellsperger KC. Effect of an arginine analogue on acetylcholine-induced coronary microvascular dilation in dogs. Am J Physiol Heart Circ Physiol 261: H2001-H2007, 1991[Abstract/Free Full Text].

14.   Fang, X, Kaduce TL, Weintraub NL, VanRollins M, and Spector AA. Functional implications of a newly-characterized pathway of 11,12-epoxyeicosatrienoic acid metabolism in arterial smooth muscle. Circ Res 79: 784-793, 1996[Abstract/Free Full Text].

15.   Feletou, M, and Vanhoutte PM. The alternative: EDHF. J Mol Cell Cardiol 31: 15-22, 1999[Web of Science][Medline].

16.   Fisslthaler, B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 401: 493-497, 1999[Medline].

17.   Fort, S, and Lewis MJ. A factor released from coronary vascular endothelium inhibits myocardial contractile performance. Am J Physiol Heart Circ Physiol 264: H830-H836, 1993[Abstract/Free Full Text].

18.   Freiman, PC, Mitchell GG, Heistad DD, Armstrong ML, and Harrison DG. Atherosclerosis impairs endothelium-dependent vascular relaxation to acetylcholine and thrombin in primates. Circ Res 58: 783-789, 1986[Abstract/Free Full Text].

19.   Fukao, M, Hattori Y, Kanno M, Sakuma I, and Kitabatake A. Evidence against a role of cytochrome P450-derived arachidonic acid metabolites in endothelium-dependent hyperpolarization by acetylcholine in rat isolated mesenteric artery. Br J Pharmacol 120: 439-446, 1997[Web of Science][Medline].

20.   Fulton, D, Mahbooubi K, McGiff JC, and Quilley J. Cytochrome P450-dependent effects of bradykinin in the rat heart. Br J Pharmacol 114: 99-102, 1995[Web of Science][Medline].

21.   Fulton, D, McGiff JC, and Quilley J. Pharmacological evaluation of an epoxide as putative hyperpolarizing factor mediating the nitric oxide-independent vasodilator effect of bradykinin in the rat heart. J Pharmacol Exp Ther 287: 497-503, 1998[Abstract/Free Full Text].

22.   Gardiner, SM, Compton AM, Bennett T, Palmer RM, and Moncada S. Control of regional blood flow by endothelium-derived nitric oxide. Hypertension 15: 486-492, 1990[Abstract/Free Full Text].

23.   Giles, WR, and Imaizumi Y. Comparison of potassium currents in rabbit atrial and ventricular cells. J Physiol 405: 123-145, 1988[Abstract/Free Full Text].

24.   Guengerich, FP, and Mason PS. Immunological comparison of hepatic and extrahepatic cytochromes P-450. Mol Pharmacol 15: 154-164, 1979[Abstract/Free Full Text].

25.   Hayashi, S, and Hester K. Endothelium-dependent relaxations in rabbit aorta are depressed in artificial buffered solutions. J Pharmacol Exp Ther 242: 523-530, 1987[Abstract/Free Full Text].

26.   Kamata, K, Miyata N, Abiru T, and Kasuya Y. Functional changes in vascular smooth muscle and endothelium of arteries during diabetes mellitus. Life Sci 50: 1379-1387, 1992[Web of Science][Medline].

27.   Kelly, RA, Balligand JL, and Smith TW. Nitric oxide and cardiac function. Circ Res 79: 363-380, 1996[Free Full Text].

28.   Kojda, G, and Kottenberg K. Regulation of basal myocardial function by NO. Cardiovasc Res 41: 514-523, 1999[Free Full Text].

29.   Kostic, MM, Petronijevic MR, and Jakovljevic VL. Role of nitric oxide (NO) in the regulation of coronary circulation. Physiol Res 45: 273-278, 1996[Web of Science][Medline].

30.   Lee, H, Lu T, Weintraub NL, Van Rollins M, Spector AA, and Shibata EF. Effects of epoxyeicosatrienoic acids on the cardiac sodium channels in isolated rat ventricular myocytes. J Physiol 519: 153-168, 1999[Abstract/Free Full Text].

31.   Losano, G, Pagliaro P, Rastaldo R, Paolocci N, Penna C, Gattullo D, and Linden RJ. The negative inotropic effects of bradykinin are mediated by cytochrome P-450 activity in the rat heart (Abstract). J Physiol 521P: 25P, 1999.

32.   Ma, L, Robinson CP, Thadani U, and Patterson E. Effect of 17-beta estradiol in the rabbit: endothelium-dependent and-independent mechanisms of vascular relaxation. J Cardiovasc Pharmacol 30: 130-135, 1997[Web of Science][Medline].

33.   Minshall, R, Yelemanchi VP, Djokovic A, Miletich DJ, Erdös EG, Rabito SF, and Vogel SM. Importance of sympathetic innervation in the positive inotropic effects of bradykinin and ramiprilat. Circ Res 74: 441-447, 1994[Abstract/Free Full Text].

34.   Minshall, RD, Vogel SM, and Rabito SF. Are the inotropic and antiarrytmic effects of bradykinin due to increases in coronary flow? Am J Cardiol 80: 148A-152A, 1997[Medline].

35.   Miura, H, and Gutterman DD. Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monoxigenase Ca2+-activated K+ channels. Circ Res 83: 501-507, 1998[Abstract/Free Full Text].

36.   Miura, H, Liu Y, and Gutterman DD. Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+ activated K+ channels. Circulation 99: 3132-3138, 1999[Abstract/Free Full Text].

37.   Moffat, MP, Ward CA, Bend JR, Mock T, Farhangkhoee P, and Karmazyn M. Effects of epoxyeicosatrienoic acids on isolated hearts and ventricular myocytes. Am J Physiol Heart Circ Physiol 264: H1154-H1560, 1993[Abstract/Free Full Text].

38.   Mombouli, J, and Vanhoutte PM. Kinins and endothelial control of vascular smooth muscle. Annu Rev Pharmacol Toxicol 35: 679-705, 1995[Web of Science][Medline].

39.   Munch, PA, and Longhurst JC. Bradykinin increases myocardial contractility: relation to the Gregg phenomenon. Am J Physiol Regulatory Integrative Comp Physiol 260: R1095-R1103, 1991[Abstract/Free Full Text].

40.   Najibi, S, and Cohen RA. Enhanced role of K+ channels in relaxations of hypercholesterolemic rabbit carotid artery to NO. Am J Physiol Heart Circ Physiol 269: H805-H811, 1995[Abstract/Free Full Text].

41.   Nakamura, T, Bratton DL, and Murphy RC. Analysis of epoxyeicosatrienoic and monohydroxyeicosatetranoic acids esterified to phospholipids in human red blood cells by electrospray tandem mass spectometry. J Mass Spectrom 32: 888-896, 1997[Web of Science][Medline].

42.   Nishikawa, Y, Stepp DW, and Chilian WM. Nitric oxide exerts feedback inhibition on EDHF-induced coronary arteriolar dilation in vivo. Am J Physiol Heart Circ Physiol 279: H459-H465, 2000[Abstract/Free Full Text].

43.   Ortiz de Montellano, PR, and Mathews JM. Autocatalytic alkylation of the cythocrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an NN-bridged benzyne protoporphyrin IX adduct. Biochem J 195: 761-764, 1981[Web of Science][Medline].

44.   Ou, YJ, Shan QX, and Bourreau JP. Endothelium-dependent effect of bradykinin and ATP on rabbit ventricular myocytes. Life Sci 64: PL291-PL296, 1999[Web of Science][Medline].

45.   Paolocci, N, Pagliaro P, Isoda T, Saavedra FW, and Kass DA. Role of calcium-sensitive K+ channels and nitric oxide in in vivo coronary vasodilation from enhanced perfusion pulsatility. Circulation 103: 119-124, 2001[Abstract/Free Full Text].

46.   Paolocci, N, Vandegaer KM, Rosas GO, Kass DA, and Hare JM. Role of intermediate Ca2+ sensitive potassium channel in bradykinin-induced myocardial contractile depression (Abstract). Circulation 102: II216, 2000[Abstract/Free Full Text].

47.   Pinto, A, Abraham NG, and Mullane KM. Arachidonic acid-induced endothelial-dependent relaxations of canine coronary arteries: contribution of a cytochrome P-450-dependent pathway. J Pharmacol Exp Ther 240: 856-863, 1987[Abstract/Free Full Text].

48.   Plesnila, N, Haberstok J, Peters J, Kolbl I, Baethmann A, and Staub F. Effect of lactacidosis on cell volume and intracellular pH of astrocytes. J Neurotrauma 16: 831-841, 1999[Web of Science][Medline].

49.   Popp, R, Bauersachs J, Hecker M, Fleming I, and Busse R. A transferable, beta-naphtoflavone-inducible, hyperpolarizing factor is synthetized by native and cultured porcine coronary endothelial cells. J Physiol 497: 699-709, 1996[Abstract/Free Full Text].

50.   Popp, R, Fleming I, and Busse R. Pulsatile stretch in coronary arteries elicits release of endothelium-derived hyperpolarizing factor: a modulator of arterial compliance. Circ Res 82: 696-703, 1998[Abstract/Free Full Text].

51.   Ringel, F, Chang RC, Staub F, Baethmann A, and Plesnila N. Contribution of anion transporters to the acidosis-induced swelling and intracellular acidification of glial cells. J Neurochem 75: 125-132, 2000[Web of Science][Medline].

52.   Sakuta, H, and Yoneda I. Inhibition of SKF 525A and quinacrine of endogenous glibenclamide-sensitive K+ channels in follicle-enclosed Xenopus oocytes. Eur J Pharmacol 252: 117-121, 1994[Web of Science][Medline].

53.   Treasure, CB, Klein JL, Vita JA, Manoukian SV, Renwick GH, Selwyn AP, Ganz P, and Alexander RW. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 87: 86-93, 1993[Abstract/Free Full Text].

54.   Van de Voorde, J, and Vanheel B. Influence of cytochrome P-450 inhibitors on endothelium-dependent nitro-L-arginine-resistant relaxation and cromakalim-induced relaxation in rat mesenteric arteries. J Cardiovasc Pharmacol 29: 827-832, 1997[Web of Science][Medline].

55.   Van Rollins, M, Kaduce TL, Knapp HR, and Spector AA. 14,15-Epoxyeicosatrienoic acid metabolism in endothelial cells. J Lipid Res 34: 1931-1947, 1993[Abstract].

56.   Vanheel, B, and Van de Voorde J. Evidence against the involvement of cytochrome P-450 metabolites in endothelium-dependent hyperpolarization of the rat main mesenteric artery. J Physiol 501: 331-341, 1997[Abstract/Free Full Text].

57.   Weintraub, NL, Fang X, Kaduce TL, Van Rollins M, Chatterjee P, and Spector AA. Potentiation of endothelium-dependent relaxation by epoxyeicosatrienoic acids. Circ Res 81: 258-262, 1997[Abstract/Free Full Text].

58.   Wu, S, Moomaw CR, Tomer KB, Falck JR, and Zeldin DC. Molecular cloning and expression of CYP2J2, a human cytochrome P450 arachidonic acid epoxygenase highly expressed in heart. J Biol Chem 271: 3460-3468, 1996[Abstract/Free Full Text].

59.   Xiao, YF, Huang L, and Morgan JP. Cytochrome P450: a novel system modulating Ca2+ channels and contraction in mammalian heart cells. J Physiol 508: 777-792, 1998[Abstract/Free Full Text].

60.   Yayama, K, Nagaoka M, Takano M, and Okamoto H. Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. Biochim Biophys Acta 1495: 69-77, 2000[Medline].

61.   Zhu, Y, Schieber EB, McGiff JC, and Balazy M. Identification of arachidonate P-450 metabolites in human platelet phospholipids. Hypertension 25: 854-859, 1995[Abstract/Free Full Text].

Am J Physiol Heart Circ Physiol 280(6):H2823-H2832
0363-6135/01 $5.00 Copyright © 2001 the American Physiological Society


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhang, H. El-Sikhry, K. R. Chaudhary, S. N. Batchu, A. Shayeganpour, T. O. Jukar, J. A. Bradbury, J. P. Graves, L. M. DeGraff, P. Myers, et al.
Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H37 - H46.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
S. Cappello, T. Angelone, B. Tota, P. Pagliaro, C. Penna, R. Rastaldo, A. Corti, G. Losano, and M. C. Cerra
Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism
Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H719 - H727.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
C. Penna, D. Mancardi, R. Rastaldo, G. Losano, and P. Pagliaro
Intermittent activation of bradykinin B2 receptors and mitochondrial KATP channels trigger cardiac postconditioning through redox signaling
Cardiovasc Res, July 1, 2007; 75(1): 168 - 177.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
C. Penna, G. Alloatti, S. Cappello, D. Gattullo, G. Berta, B. Mognetti, G. Losano, and P. Pagliaro
Platelet-activating factor induces cardioprotection in isolated rat heart akin to ischemic preconditioning: role of phosphoinositide 3-kinase and protein kinase C activation
Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2512 - H2520.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Ohta, N. Hasebe, S. Tsuji, K. Izawa, Y.-T. Jin, S. Kido, S. Natori, M. Sato, and K. Kikuchi
Unequal effects of renin-angiotensin system inhibitors in acute cardiac dysfunction induced by isoproterenol
Am J Physiol Heart Circ Physiol, December 1, 2004; 287(6): H2914 - H2921.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
J. Seubert, B. Yang, J. A. Bradbury, J. Graves, L. M. Degraff, S. Gabel, R. Gooch, J. Foley, J. Newman, L. Mao, et al.
Enhanced Postischemic Functional Recovery in CYP2J2 Transgenic Hearts Involves Mitochondrial ATP-Sensitive K+ Channels and p42/p44 MAPK Pathway
Circ. Res., September 3, 2004; 95(5): 506 - 514.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
U. Kreutzer and T. Jue
Role of myoglobin as a scavenger of cellular NO in myocardium
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H985 - H991.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rastaldo, R.
Right arrow Articles by Pagliaro, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rastaldo, R.
Right arrow Articles by Pagliaro, P.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online